Toshiaki Iwase

Assistant professor, Investigator-Initiated Early Phase Clinical Trial Development and Regulatory Director

University of Hawai'i Cancer Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Toshiaki Iwase is an Assistant Professor and Investigator-Initiated Early Phase Clinical Trial Development and Regulatory Director at the University of Hawai'i Cancer Center. His research primarily focuses on breast cancer, with recent articles exploring targets for enhancing antitumor activity, immunomodulatory gene signatures, and the prognostic impact of body composition in breast cancer treatment. Dr. Iwase's work also includes clinical trials evaluating combination therapies and the pathological response in inflammatory breast cancer.

Articles (10)

Year:

2023

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (2)

Naoto Ueno

Professor of Medicine

University of Hawai'i Cancer Center

UNITED STATES

View details

Yu Shen

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Toshiaki Iwase

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines

A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer.

PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening

Changes in Overall Survival over Time for Patients with de novo Metastatic Breast Cancer

The Prognostic Impact of Body Composition for Locally Advanced Breast Cancer Patients Who Received Neoadjuvant Chemotherapy

Body composition and breast cancer risk and treatment: mechanisms and impact.

Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy for inflammatory breast cancer: A systematic review

Validation of Prognostic Stage and Anatomic Stage in the American Joint Committee on Cancer 8th Edition for Inflammatory Breast Cancer

Targeting Signaling Pathways in Inflammatory Breast Cancer

Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer

Collaborators (2)

Naoto Ueno

Yu Shen

Make your next move.